The early diagnosis of Alzheimer’s disease: a patient-centred conversation with the care team

Raising the bar in Drug-resistant Focal Onset Seizures: any improvements in sight?

Have we realised the full potential of S1P receptor modulation in MS?

Clinical conversations in migraine - we can help!

Adults with SMA: the beginning of a new chapter 

Advancing MS Care: Addressing the Patient Experience

New perspectives in the management of rare early-onset epilepsies: beyond seizures

Removing the barriers to optimal migraine care: Are we listening to the evidence?

We need to talk about Brain Health and Alzheimer’s

Motor fluctuation management: now and what next?

Complement inhibition in neuromyelitis optica spectrum disorder and refractory generalized myasthenia gravis;
From trials to real-world clinical practice

Partnering with patients from the start of the MS journey: Priorities, practicalities and progress

Overcoming barriers in MS care: optimising treatment for patients

AbbVie: Personalizing Care for Patients With Parkinson’s Disease and Uncontrolled Symptoms: Optimizing Identification and Joint Treatment Decisions 

Current and future approaches to migraine prevention

Gene, Patient, Clinician: Principles of Targeted Therapies in Spinal Muscular Atrophy (SMA)

ATTR amyloidosis – navigating this multifaceted disease

Managing Epilepsy in a COVID world

AMBER: Plasma Exchange plus albumin replacement as an innovative treatment for Alzheimer’s disease

Implications of the first Ex-vivo Gene therapy approved for treating early onset MLD’ 

Continuing tales of the unexpected; unravelling the mystery of an earlier diagnosis in muscle disease

Transforming outcomes and the goals for care in the 21st century

The evolution of infusion therapy for PD – translating clinical progress into personalised solutions

Balancing COVID-19 challenges and long-term treatment of MS

Management of Relapsing-Remitting Multiple Sclerosis with an S1P Receptor Modulator

The Effect of an S1P Receptor Modulator on Cognitive Processing in Patients with Relapsing-Remitting Multiple Sclerosis

Quantitative Brain Volume Assessment: Past, Present, and Future

Clarity on cannabinoids: test your knowledge

How important is an evidence-based approach for cannabis-based products and medicines?

Conversations on cannabinoids: tackling the big questions

The hidden drivers of disease progression: peering behind the blood brain barrier

Unmasking spms: challenging the dogma

Facing the challenge: managing disease progression

Starting the AD journey: identifying a potential patient

Continuing the AD journey: providing a diagnosis

Overseeing the AD journey: treating and monitoring care

Adults with SMA: To treat or not to treat?

Genetic ALS − Epidemiology and testing

Adults with SMA: How to define treatment response?

One to 14: the heterogeneity and consequences of episodic migraine

Chronic migraine: more than a headache

Medication-overuse headache (MOH): when the treatment becomes the problem

The future of migraine treatment paradigm

Gene Therapy: Neurology to Lead or Follow?

Best practice in management of patients with Lennox-Gastaut syndrome on cannabidiol: experts’ clinical cases

GENE THERAPY: addressing the unmet needs of neuromuscular disorders

Resolution, reproducibility, noise and quality of electrodiagnostic recordings